August 13, 2019 Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases
August 9, 2019 Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
July 24, 2019 Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Acute Myeloid Leukemia
May 23, 2019 Mustang Bio and St. Jude Children’s Research Hospital to Participate in Panel Discussion at Boston CEO 2019
May 16, 2019 Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 (Oncolytic Virus C134) for the Treatment of Malignant Glioma
May 10, 2019 Mustang Bio Reports First Quarter 2019 Financial Results and Recent Corporate Highlights